Joanna Cooper, MD
Neurology · Berkeley, CANPI 1558477018
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,073 of the $7,500 with a category attached, or 67.6%. 22 manufacturers reported payments, led by Genentech, Inc. at 27.3% of the total. Reporting peaked in 2022 at $2,502 and has fallen 81.0% since, to $476 in 2025.
Across 77 payments — averaging $97.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2K
- AstraZeneca$1K
- Novartis$814
- Biogen$693
- Sanofi$450
- Amgen$446
- plus $2K from 16 others
Across 143 payments — averaging $15,503 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$810K
- Genentech, Inc.$594K
- AbbVie$373K
- Sanofi$189K
- Biogen$98K
- Hoffmann-la Roche Limited$88K
- plus $64K from 3 others
What the payments were for
- Grants$2,04527%
- Travel & lodging$431%
- Food & beverage$5,07368%
- Education$3395%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $2,045 |
| AstraZeneca | 13 | $1,180 |
| Novartis | 8 | $814 |
| Biogen | 10 | $693 |
| Sanofi | 5 | $450 |
| Amgen(2 entities) | 5 | $446 |
| Bristol Myers Squibb | 13 | $387 |
| AbbVie(2 entities) | 3 | $359 |
| SK Life Science, Inc. | 5 | $237 |
| Genentech USA, Inc. | 1 | $146 |
| TG Therapeutics, Inc. | 1 | $140 |
| Harmony Biosciences LLC | 2 | $121 |
| Lilly USA, LLC | 1 | $109 |
| EMD Serono, Inc. | 1 | $108 |
| Otsuka America Pharmaceutical, Inc. | 1 | $86 |
| Jazz Pharmaceuticals Inc. | 1 | $45 |
| Itamar Medical Inc | 1 | $32 |
| Resmed Corp | 1 | $29 |
| Piramal Critical Care | 1 | $22 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Medtronic | 1 | $16 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,500 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriflunomide | 72 | $92,141 |
| HorizantGabapentin Enacarbil | 18 | $26,665 |
| GlatopaGlatiramer Acetate | 22 | $23,657 |
| UbrelvyUbrogepant | 14 | $16,171 |
| Lacosamide | 28 | $10,231 |
| LamictalLamotrigine | 12 | $10,012 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $9,617 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,251 |
| Dimethyl Fumarate | 14 | $2,777 |
| Clobazam | 12 | $2,695 |
| Levetiracetam | 61 | $2,478 |
| Baclofen | 72 | $2,173 |
| Gabapentin | 73 | $1,869 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $1,430 |
| Pregabalin | 37 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $359 | $16,17114 claims |
| GSKLamictal | $15 | $10,01212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Berkeley
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.